Towards New Anti‐Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2
ChemMedChem · 2025
DOI: 10.1002/cmdc.202400567 ↗At a glance
Journal article in ChemMedChem, 2025. Written by Marc Farag and 15 co-authors. Institution: Department, Normandie Univ, UNICAEN, CERMN, bd Becquerel, F-14000, Caen, Cedex, France. Major MEDLINE topics: X-Linked Inhibitor of Apoptosis Protein, Drug Design, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents. Cited 2 times so far (Crossref); 58 references. Funded by: European Community (ERDF: European Regional Development Fund).
Abstract (original language)
The X‐chromosome‐linked inhibitor of apoptosis protein (XIAP) plays a crucial role in controlling cell survival across multiple regulated cell death pathways and coordinating a range of inflammatory signalling events. The discovery of selective inhibitors for XIAP‐BIR2, able to disrupt the direct physical interaction between XIAP and RIPK2, offer promising therapeutic options for NOD2‐mediated diseases like Crohn's disease, sarcoidosis, and Blau syndrome. The objective of this study was to design, synthesize, and evaluate small synthetic molecules with binding selectivity to XIAP‐BIR2 domain. To achieve this, we applied an interdisciplinary drug design approach and firstly we have synthesized an initial fragment library to achieve a first XIAP inhibition activity. Then using a growing strategy, larger compounds were synthesized and one of them presents a good selectivity for XIAP‐BIR2 versus XIAP‐BIR3 domain, compound 20 c . The ability of compound 20 c to block the NOD1/2 pathway was confirmed in cell models. These data show that we have synthesized molecules capable of blocking NOD1/2 signalling pathways in cellulo , and ultimately leading to new anti‐inflammatory compounds.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department, Normandie Univ, UNICAEN, CERMN, bd Becquerel, F-14000, Caen, Cedex, France.
- Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France.
- Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France.
- Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France.
ORCID profiles: Nicolas Guedeney, Florian Schwalen, Marc Since, Anne Sophie Voisin-Chiret, Laurence Dubrez, Charline Kieffer
Funding
- European Community (ERDF: European Regional Development Fund)
Cite
APA
Farag, M., Guedeney, N., Schwalen, F., Zadoroznyj, A., Barczyk, A., Giret, M., Antraygues, K., Wang, A., Cornu, M., Suzanne, P., Since, M., Sophie Voisin-Chiret, A., Dubrez, L., Leleu-Chavain, N., Kieffer, C., & Sopkova-de Oliveira Santos, J. (2025). Towards New Anti‐Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2. ChemMedChem. https://doi.org/10.1002/cmdc.202400567
Vancouver
Farag M, Guedeney N, Schwalen F, Zadoroznyj A, Barczyk A, Giret M, et al. Towards New Anti‐Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2. ChemMedChem. 2025. doi:10.1002/cmdc.202400567
BibTeX
@article{Farag2025,
author = {Farag, Marc and Guedeney, Nicolas and Schwalen, Florian and Zadoroznyj, Aymeric and Barczyk, Amélie and Giret, Martin and Antraygues, Kevin and Wang, Alice and Cornu, Marie and Suzanne, Peggy and Since, Marc and Sophie Voisin-Chiret, Anne and Dubrez, Laurence and Leleu-Chavain, Natascha and Kieffer, Charline and Sopkova-de Oliveira Santos, Jana},
title = {Towards New Anti‐Inflammatory Agents: Design, Synthesis and Evaluation of Molecules Targeting XIAP‐BIR2},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202400567}
}
EUVIMED